Solventum Corporation Common Stock (SOLV)

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSESOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on Solventum’s recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc NYSE: TMONYSETMO)

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics.

Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company

September may have a reputation, but investors can find opportunities for growth and value by focusing on solid fundamentals and business models.

3M's fall from grace is at an end, the stock rebound is gaining momentum after better-than-expected results that point to growth and distribution increases.

3M is a high-quality dividend-paying stock with diminishing headwinds and catalysts forming that could increase the market by 50%.

Three stocks have fallen into value investor radars, as they provide double-digit discounts to their peers and still generate above-average returns on capital

3M stock is still worth double-digit upside, the spinoff of its healthcare division could only boost more dividend payments and growth acquisitions